CD200 Receptor Monoclonal Antibody (OX108), Functional Grade, eBioscience™, Invitrogen™

Description

Description: The monoclonal antibody OX108 recognizes human CD200R also known as OX2. CD200R is an inhibitory receptor with a similar structure as its ligand, CD200, yet lacks an ITIM domain typically found in inhibitory receptors. Instead the CD200R cytoplasmic domain contains a novel phosphotyrosine binding domain, NPXY, which after binding SHIP inhibits ERK, JNK and MAPK p38 pathways. In activated macrophages signaling results in inhibition of TNFalpha secretion. Isoforms of CD200R have been identified and are thought to play a major role in differentiation, especially in regards to tolerogenic DCs. Expression is restricted to hematopoietic cells: myeloid cells (monocytes, macrophages, DCs, neutrophils, mast cells and basophils) and a subset of T lymphocytes as well as langerhans (LC) cells and dendritic epidermal T cells. The epitope of OX108 is thought to be near the binding site of CD200. Applications Reported: This OX108 antibody has been reported for use in flow cytometric analysis and functional assays. Applications Tested: This OX108 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

CD200R (OX2R) is a receptor for the OX-2 membrane glycoprotein, and both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains. CD200R is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal. In mouse, CD200R is expressed primarily by peripheral blood monocytes and neutophils but also by other leucocytes including T-lymphocytes and mast cells. Further mouse studies of a gene related to CD200R suggests that the receptor may control myeloid function in a tissue-specific manner. Alternative splicing of CD200R results in multiple transcript variants. Diseases associated with CD200R dysfunction include primary hypertrophic osteoarthropathy.